ESR1 and breast cancer: As a result, a potential approach to treating non-luminal breast cancers is to reactivate ER activity through drugs such as 5-aza-2`deoxycytidine (5-aza) or Trichostatin A (TSA), and then apply TAM treatment or chemotherapy [8, 11, 12].